Evaluation of the effectiveness of the use of rifampicin to prevent leprosy in contacts of patients with multibacillary form

Phase 4

Recruiting

• Conditions: eprosy, chemoprevention, clinical trial, rifampicin.; E02.319.162; V03.175.250; D03.633.400.811.700

• Registration Number: RBR-69qk5p
• Lead Sponsor: Instituto Oswaldo Cruz - Laboratório de Hanseníase

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-06-01
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: Not specified

Inclusion Criteria

Contacts of patients with multibacillary leprosy who agreed to undergo chemoprophylaxis; age from 6 months to 70 years; willingness to undergo clinical and anti-PGL-1 evaluation; availability for follow-up; return for vaccination in two months and for clinic evaluation in 12 months.

Exclusion Criteria

Clinical or laboratory confirmation of leprosy at baseline; BCG vaccination in the preceding 12 months, except for infants between 6 and 12 months of age; contacts with immunosuppression or history of tuberculosis in all its forms; pregnancy at any stage, or refusal to undergo urine pregnancy test and refusal to sign the informed consent form (ICF).

Study & Design

• Study Type: Intervention
• Study Design: Not specified